

## Purified anti-mouse CD45 Antibody

<b>Catalog# / Size</b>	103101 / 50 µg 103102 / 500 µg
<b>Clone</b>	30-F11
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	T200, Ly-5, LCA
<b>Isotype</b>	Rat IgG2b, κ
<b>Description</b>	CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

### Product Details

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	Mouse thymus or spleen
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography.
<b>Concentration</b>	0.5 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C.
<b>Application</b>	<a href="#">FC - Quality tested</a> <a href="#">IHC-F, CyTOF® - Verified</a> <a href="#">IP, CMCD, IHC, WB - Reported in the literature, not verified in house</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 <sup>6</sup> cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Application Notes</b>	Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.  Additional reported applications (for relevant formats) include: immunoprecipitation <sup>3</sup> , complement-dependent cytotoxicity <sup>1,5</sup> , immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections) <sup>4,6</sup> , Western blotting <sup>7</sup> , and spatial biology (IBEX) <sup>10,11</sup> . The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).
<b>Application References</b>	<ol style="list-style-type: none"> <li>1. Podd BS, <i>et al.</i> 2006. <i>J. Immunol.</i> 176:6532. (FC, CMCD) <a href="#">PubMed</a></li> <li>2. Haynes NM, <i>et al.</i> 2007. <i>J. Immunol.</i> 179:5099. (FC)</li> <li>3. Ledbetter JA, <i>et al.</i> 1979. <i>Immunol. Rev.</i> 47:63. (IP)</li> <li>4. Simon DI, <i>et al.</i> 2000. <i>J. Clin. Invest.</i> 105:293. (IHC)</li> <li>5. Seaman WE. 1983. <i>J. Immunol.</i> 130:1713. (CMCD)</li> <li>6. Cornet A, <i>et al.</i> 2001. <i>P. Natl. Acad. Sci. USA</i> 98:13306. (IHC)</li> <li>7. Tsuboi S and Fukuda M. 1998. <i>J. Biol. Chem.</i> 273:30680. (WB) <a href="#">PubMed</a></li> <li>8. Liu F, <i>et al.</i> 2012. <i>Blood.</i> 119:3295. <a href="#">PubMed</a></li> <li>9. Pelletier AN, <i>et al.</i> 2012. <i>J. Immunol.</i> 188:5561. <a href="#">PubMed</a></li> <li>10. Radtke AJ, <i>et al.</i> 2020. <i>Proc Natl Acad Sci U S A.</i> 117:33455-65. (SB) <a href="#">PubMed</a></li> <li>11. Radtke AJ, <i>et al.</i> 2022. <i>Nat Protoc.</i> 17:378-401. (SB) <a href="#">PubMed</a></li> </ol>
<b>(PubMed link indicates BioLegend citation)</b>	

## Product Citations

1. Hernández-Santana YE, *et al.* 2020. Life Sci Alliance. 3:00. [PubMed](#)
2. Claveria-Cabello A, *et al.* 2020. Cancers (Basel). 12:00. [PubMed](#)
3. Davies M, *et al.* 2017. PLoS Pathogens. 13(6):e1006435. [PubMed](#)
4. Axelrod HD, *et al.* 2019. Mol Cancer Res. 17:356. [PubMed](#)
5. Schneider H, *et al.* 2017. J Neurochem. 140:170. [PubMed](#)
6. Shafer MER, *et al.* 2017. Stem Cell Reports. 1.040277778. [PubMed](#)
7. Arnold IC, *et al.* 2019. PLoS Pathog. 15:e1007866. [PubMed](#)
8. Wolf Y, *et al.* 2017. J Exp Med. 214:905. [PubMed](#)
9. Hutton C, *et al.* 2021. Cancer Cell. 39:1227. [PubMed](#)
10. Blomberg E, *et al.* 2022. Neurooncol Adv. 4:vdac148. [PubMed](#)
11. Murai K, *et al.* 2022. Nat Commun. 13:6206. [PubMed](#)
12. Reglero-Real N, *et al.* 2021. Immunity. .: [PubMed](#)
13. Chamberlin T, *et al.* 2020. Cancer Research. 80(20):4465-4475. [PubMed](#)
14. Li X, *et al.* 2020. Cell Rep. 31:107765. [PubMed](#)
15. Vitiello GA, *et al.* 2018. Clin Cancer Res. 24:972. [PubMed](#)
16. Rothchild AC, *et al.* 2019. Sci Immunol. 4:eaaw6693. [PubMed](#)
17. Widjaja AA, *et al.* 2019. Gastroenterology. 157:777. [PubMed](#)
18. Kondo H, *et al.* 2020. J Biol Chem. 295:1658. [PubMed](#)
19. Fernandes V, *et al.* 2020. PLoS Pathog. 16:e1008464. [PubMed](#)
20. Nguyen R, *et al.* 2021. Cancer Immunol Immunother. 70:721. [PubMed](#)
21. Wan Mohd Zawawi WFA, *et al.* 2021. Sci Rep. 11:10278. [PubMed](#)
22. Maestro S, *et al.* 2021. Viruses. 13: . [PubMed](#)
23. Moon H *et al.* 2017. Cell stem cell. 21(5):665-678 . [PubMed](#)
24. Rieck M, *et al.* 2017. Eur J Immunol. 47:677. [PubMed](#)
25. Ajona D, *et al.* 2017. Cancer Discov. 0.773611111. [PubMed](#)
26. Goel S, *et al.* 2017. Nature. 548:471. [PubMed](#)
27. Wang W, *et al.* 2018. Cancer Cell. 34:757. [PubMed](#)
28. Paulo E, *et al.* 2018. Sci Rep. 8:11001. [PubMed](#)
29. Arnold IC, *et al.* 2018. J Exp Med. 215:2055. [PubMed](#)
30. Heinrich A, *et al.* 2021. Cell Rep. 37:109885. [PubMed](#)
31. Cooper STE, *et al.* 2022. Int J Mol Sci. 23: . [PubMed](#)
32. Deppermann C, *et al.* 2020. J Exp Med. 217: . [PubMed](#)
33. Liu X, *et al.* 2020. Nature. . [PubMed](#)
34. Altshuler A, *et al.* 2021. Cell Stem Cell. 28(7):1248-1261.e8. [PubMed](#)
35. Parlanti P, *et al.* 2020. Exp Eye Res. 194:107998. [PubMed](#)
36. Lee S, *et al.* 2020. Cell Host & Microbe. 27(6):937-949. [PubMed](#)
37. Thulasingham S, *et al.* 2019. Int J Mol Sci. 20. [PubMed](#)
38. Gao J, *et al.* 2017. Oncol Lett. 14:2954. [PubMed](#)
39. Starossom SC, *et al.* 2019. Nat Commun. 10:217. [PubMed](#)
40. Dertschnig S, *et al.* 2020. J Clin Invest. 130:1896. [PubMed](#)
41. Gao H, *et al.* 2021. J Virol. .: [PubMed](#)
42. Dienz O, *et al.* 2020. J Immunol. 204:1521. [PubMed](#)
43. Karhadkar TR, *et al.* 2021. J Pharmacol Exp Ther. 376:106. [PubMed](#)
44. Schafflick D, *et al.* 2020. Nat Commun. 247:11. [PubMed](#)
45. Zabaleta N, *et al.* 2018. Nat Commun. 9:5454. [PubMed](#)
46. Zhu F, *et al.* 2019. J Immunol. 203:2644. [PubMed](#)
47. Li Y *et al.* 2019. Endocrinology. 160(4):938-946 . [PubMed](#)
48. Murad JP, *et al.* 2018. Front Immunol. 1.95. [PubMed](#)
49. Go DM, *et al.* 2021. Cell Mol Gastroenterol Hepatol. 12:715. [PubMed](#)
50. Wang G, *et al.* 2021. Nat Commun. 12:5733. [PubMed](#)
51. Quintana E, *et al.* 2020. Cancer Res. 80:2889. [PubMed](#)
52. Stefanescu C, *et al.* 2021. Front Oncol. 11:765151. [PubMed](#)
53. Paprckova D, *et al.* 2022. Front Immunol. 13:1009198. [PubMed](#)
54. Podd B, *et al.* 2006. J Immunol. 176:6532. [PubMed](#)
55. Hitchcock JR, *et al.* 2020. FEBS J. 287:250. [PubMed](#)
56. McLeod RL, *et al.* 2018. Oncotarget. 9:34459. [PubMed](#)
57. Sutton C, *et al.* 2017. Nat Commun.. 10.1038/s41467-017-02111-0. [PubMed](#)
58. Janghorban M, *et al.* 2022. Cancer Res. 82:885. [PubMed](#)
59. Jackson JW, *et al.* 2021. Mol Ther Oncolytics. 22:444. [PubMed](#)
60. Mayer KA, *et al.* 2021. FASEB J. 35:e21217. [PubMed](#)
61. Delgobo M, *et al.* 2021. Front Immunol. 12:584538. [PubMed](#)
62. Baraibar-Churio A, *et al.* 2021. Life (Basel). 11: . [PubMed](#)
63. Nam J, *et al.* 2021. Front Cell Neurosci. 15:640084. [PubMed](#)
64. Park S, *et al.* 2021. Nat Cell Biol. 23:476. [PubMed](#)
65. Hagan AS, *et al.* 2020. Development. 147:00:00. [PubMed](#)
66. Rhee S, *et al.* 2018. Nat Commun. 9:368. [PubMed](#)
67. Finn J *et al.* 2019. Cell reports. 26(11):2942-2954 . [PubMed](#)
68. Nolin JD, *et al.* 2017. JCI Insight. 2:e94929. [PubMed](#)
69. Fiege JK, *et al.* 2019. PLoS Pathog. 15:e1008077. [PubMed](#)
70. Silvestre-Roig C, *et al.* 2019. Nature. 569:236. [PubMed](#)
71. Melchor SJ, *et al.* 2020. Sci Rep. 10:15724. [PubMed](#)
72. O'Dea KP, *et al.* 2020. J Extracell Vesicles. 9:1706708. [PubMed](#)
73. Baluk P, *et al.* 2020. Am J Pathol. 190:2355. [PubMed](#)
74. Suzuki Y, *et al.* 2021. FEBS Open Bio. 11:2619. [PubMed](#)
75. Gil-Melgosa L, *et al.* 2021. Biomedicine. 10: . [PubMed](#)
76. Karhadkar TR, *et al.* 2021. PLoS One. 16:e0245924. [PubMed](#)
77. Gereke M, *et al.* 2012. J Vis Exp. 70: 4322. [PubMed](#)
78. Seelige R, *et al.* 2018. Sci Rep. 8:13670. [PubMed](#)

79. Yoshihara S, *et al.* 2019. *Front Immunol.* 0.545833333. [PubMed](#)
80. Mrdjen D *et al.* 2018. *Immunity.* 48(2):380-395 . [PubMed](#)
81. He LD, *et al.* 2021. *EMBO Rep.* 22:e52196. [PubMed](#)
82. Yim AKY, *et al.* 2022. *Nat Neurosci.* 25:238. [PubMed](#)
83. Singh PP, *et al.* 2021. *Ocul Surf.* 21:271. [PubMed](#)
84. Cassidy BR, *et al.* 2020. *J Neuroinflammation.* 17:259. [PubMed](#)
85. Fu H, *et al.* 2020. *Front Immunol.* 11:595813. [PubMed](#)
86. Peralta Ramos JM, *et al.* 2017. *Front Immunol.* 1.490277778. [PubMed](#)
87. Ito S, *et al.* 2020. *PLoS One.* 15:e0229888. [PubMed](#)
88. Latasa M, *et al.* 2010. *PLoS One.* 5:e15690. [PubMed](#)
89. Progzatky F, *et al.* 2021. *Nature.* 599:125. [PubMed](#)
90. Bruno KA, *et al.* 2021. *Int J Mol Sci.* 22:. [PubMed](#)
91. Crawford LB, *et al.* 2020. *Microorganisms.* 8:. [PubMed](#)
92. Liu H, *et al.* 2020. *J Immunol.* 205:1207. [PubMed](#)
93. Shokirova H, *et al.* 2021. *Sci Rep.* 11:8647. [PubMed](#)
94. Brown IK, *et al.* 2021. *PLoS Pathog.* 17:e1009602. [PubMed](#)
95. Kenswil KJG, *et al.* 2021. *Cell Stem Cell.* 28(4):653-670.e11. [PubMed](#)
96. Zareie P, *et al.* 2017. *J Neuroinflammation.* 0.630555556. [PubMed](#)
97. Qiu X, *et al.* 2018. *Lab Chip.* 18:2776. [PubMed](#)
98. Tsubaki T, *et al.* 2018. *Oncotarget.* 9:11209. [PubMed](#)
99. Hoves S, *et al.* 2018. *J Exp Med.* 215:859. [PubMed](#)
100. Vu LT, *et al.* 2019. *J Extracell Vesicles.* 8:1599680. [PubMed](#)
101. Jones KB *et al.* 2018. *Cell stem cell.* 24(1):183-192 . [PubMed](#)
102. Zhong L, *et al.* 2022. *JCI Insight.* 7:. [PubMed](#)
103. Nikolaou K, *et al.* 2014. *EMBO J.* 34:430. [PubMed](#)
104. Murai K *et al.* 2018. *Cell stem cell.* 23(5):687-699 . [PubMed](#)
105. Morita S *et al.* 2017. *Cell metabolism.* 25(4):883-897 . [PubMed](#)
106. Sheppard S, *et al.* 2018. *Front Immunol.* 1.630555556. [PubMed](#)
107. Davies CL, *et al.* 2019. *Front Immunol.* 10:1048. [PubMed](#)
108. Paharik AE, *et al.* 2017. *Cell Host Microbe.* 22:746. [PubMed](#)
109. Johnson SA, *et al.* 2021. *Eur J Immunol.* 51:3228. [PubMed](#)
110. Schuler CF, *et al.* 2020. *Allergy.* 75:2279. [PubMed](#)
111. Yoon S, *et al.* 2020. *Antioxidants (Basel).* 10:. [PubMed](#)
112. Hashimoto M, *et al.* 2021. *J Neurochem.* 156:834. [PubMed](#)
113. Tao H, *et al.* 2021. *Front Immunol.* 12:623280. [PubMed](#)
114. Scur M, *et al.* 2022. *Nat Commun.* 13:7272. [PubMed](#)
115. Karhadkar TR, *et al.* 2020. *bioRxiv.* . [PubMed](#)
116. Chen Q, *et al.* 2021. *STAR Protocols.* 2(1):100241. [PubMed](#)
117. Matsuo K, *et al.* 2018. *J Invest Dermatol.* 138:1764. [PubMed](#)
118. Bar O, *et al.* 2020. *Fluids Barriers CNS.* 17:27. [PubMed](#)
119. Langer V, *et al.* 2019. *J Clin Invest.* 129:4691. [PubMed](#)
120. Poulos MG, *et al.* 2017. *J Clin Invest.* 127:4163. [PubMed](#)
121. Janela B, *et al.* 2019. *Immunity.* 50:1069. [PubMed](#)
122. Lopes N, *et al.* 2021. *Nat Immunol.* 22:179. [PubMed](#)
123. Perdigoto AL, *et al.* 2022. *JCI Insight.* 7:. [PubMed](#)
124. Ejima R, *et al.* 2021. *Nutrients.* 13:. [PubMed](#)
125. Hu CF, *et al.* 2021. *Front Immunol.* 12:638381. [PubMed](#)
126. Prizant H, *et al.* 2021. *Cell Reports.* 36(6):109523. [PubMed](#)
127. Yu W, *et al.* 2020. *J Clin Invest.* . [PubMed](#)
128. Baluk P, *et al.* 2018. *Methods Mol Biol.* 1846:161. [PubMed](#)
129. Fino KK, *et al.* 2017. *Sci Rep.* 5.334722222. [PubMed](#)
130. Mensurado S, *et al.* 2018. *PLoS Biol.* 16:e2004990. [PubMed](#)
131. Geng T, *et al.* 2021. *J Infect Dis.* 223:2186. [PubMed](#)
132. Ishigaki K, *et al.* 2021. *Sci Rep.* 11:13958. [PubMed](#)
133. Tsukui H, *et al.* 2020. *BMC Cancer.* 20:411. [PubMed](#)
134. Somasundaram R, *et al.* 2021. *Blood.* 137:3037. [PubMed](#)
135. Kim D, *et al.* 2019. *Immune Netw.* 19:e32. [PubMed](#)
136. Chen X, *et al.* 2019. *Methods Mol Biol.* 2048:131. [PubMed](#)
137. Nagatake T, *et al.* 2018. *J Allergy Clin Immunol.* 142:470. [PubMed](#)
138. Moon H, *et al.* 2019. *Nat Commun.* 10:2225. [PubMed](#)
139. Wang Z, *et al.* 2021. *Drug Discov Ther.* 14:304. [PubMed](#)
140. Levy BD, *et al.* 2020. *J Allergy Clin Immunol.* 145:335. [PubMed](#)
141. Seo SU, *et al.* 2021. *Front Immunol.* 12:697162. [PubMed](#)
142. Cha J, *et al.* 2015. *J Biol Chem.* 290:15337. [PubMed](#)
143. Mori Y, *et al.* 2021. *Diabetes and Vascular Disease Research.* 18(3):14791641211027324. [PubMed](#)
144. Roussey JA, *et al.* 2017. *J Immunol.* 199:3535. [PubMed](#)
145. Tamburini BAJ, *et al.* 2019. *Front Immunol.* 10:1036. [PubMed](#)
146. Dora D, *et al.* 2021. *Cell Mol Gastroenterol Hepatol.* 12:1617. [PubMed](#)
147. Fahy N, *et al.* 2021. *Front Immunol.* 12:715267. [PubMed](#)
148. Brownlie D, *et al.* 2021. *J Immunother Cancer.* 9:. [PubMed](#)
149. Rincón E, *et al.* 2017. *Oncotarget.* 8:45415. [PubMed](#)
150. Deng W *et al.* 2019. *Cell reports.* 27(6):1755-1768 . [PubMed](#)
151. Van Der Zande HJP, *et al.* 2021. *FASEB J.* 35:e21331. [PubMed](#)
152. Penny HL, *et al.* 2021. *Int J Mol Sci.* 22:. [PubMed](#)
153. DeFalco T, *et al.* 2014. *Proc Natl Acad Sci U S A.* 111:2384. [PubMed](#)
154. Li Y, *et al.* 2020. *Elife.* 9:00. [PubMed](#)
155. Chao Y, *et al.* 2020. *Sci Adv.* 6:eaaz4204. [PubMed](#)
156. Lee YJ, *et al.* 2018. *Front Microbiol.* 9:83. [PubMed](#)
157. Heinrich A, *et al.* 2020. *Cell Rep.* 31:107513. [PubMed](#)

158. Parodi B, *et al.* 2021. *Front Immunol.* 12:655212. [PubMed](#)
159. Mohrin M, *et al.* 2021. *Aging Cell.* 20:e13313. [PubMed](#)
160. Cané S, *et al.* 2021. *J Immunother Cancer.* 9:. [PubMed](#)
161. Udumula MP, *et al.* 2021. *Mol Metab.* 53:101272. [PubMed](#)
162. Aikawa S, *et al.* 2020. *Cell Death Differ.* 1489:27. [PubMed](#)
163. Diao J, *et al.* 2018. *J Immunol.* 201:1306. [PubMed](#)
164. Pushalkar S, *et al.* 2018. *Cancer Discov.* 0.613194444. [PubMed](#)
165. Burton OT, *et al.* 2018. *Clin Exp Allergy.* 48:288. [PubMed](#)
166. Stokes KL, *et al.* 2019. *Oncogenesis.* 8:24. [PubMed](#)
167. Krenzlin H, *et al.* 2019. *J Clin Invest.* 130:1671. [PubMed](#)
168. Winter C, *et al.* 2018. *Cell Metab.* 28:175. [PubMed](#)
169. Huppé CA, *et al.* 2018. *Mucosal Immunol.* 0.536111111. [PubMed](#)
170. Van Winkle JA, *et al.* 2020. *J Virol.* 94:. [PubMed](#)
171. Maier B, *et al.* 2020. *Nature.* 580:257. [PubMed](#)
172. Wang J, *et al.* 2021. *Am J Cancer Res.* 11:2005. [PubMed](#)
173. Kästle M, *et al.* 2020. *Cell Commun Signal.* 183:18. [PubMed](#)
174. Bernard S, *et al.* 2018. *J Mammary Gland Biol Neoplasia.* 23:249. [PubMed](#)
175. Leist SR, *et al.* 2019. *PLoS One.* 14:e0220126. [PubMed](#)
176. Zhang J, *et al.* 2019. *Onco Targets Ther.* 12:4985. [PubMed](#)
177. Hassel C, *et al.* 2021. *Front Immunol.* 12:754661. [PubMed](#)
178. Obst J, *et al.* 2020. *Front Immunol.* 11:579000. [PubMed](#)
179. Dubik M, *et al.* 2021. *Front Neurosci.* 15:682451. [PubMed](#)
180. Shao Y, *et al.* 2017. *Onco Targets Ther.* 10:2675. [PubMed](#)
181. He X, *et al.* 2017. *Cancer Biol Ther.* 0.815277778. [PubMed](#)
182. Haber AL, *et al.* 2017. *Nature.* 551:333. [PubMed](#)
183. Emrick JJ, *et al.* 2018. *Proc Natl Acad Sci U S A.* 115:E12091. [PubMed](#)
184. Seehus CR, *et al.* 2017. *Nat Commun.* 8:1900. [PubMed](#)
185. Cédile O, Włodarczyk A, and Owens T 2017. *APMIS.* 10.1111/apm.12740. [PubMed](#)
186. Wilke JBH, *et al.* 2021. *Mol Psychiatry.* 26:7746. [PubMed](#)
187. Umeda M, *et al.* 2021. *Proc Natl Acad Sci U S A.* 118:. [PubMed](#)
188. Kästele V, *et al.* 2021. *Mucosal Immunol.* 14:717. [PubMed](#)

**RRID** AB\_312966 (BioLegend Cat. No. 103101)  
 AB\_312967 (BioLegend Cat. No. 103102)

## Antigen Details

<b>Structure</b>	Protein tyrosine phosphatase (PTP) family, 180-240 kD
<b>Distribution</b>	All hematopoietic cells except mature erythrocytes and platelets
<b>Function</b>	Phosphatase, T and B cell activation
<b>Ligand/Receptor</b>	Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
<b>Cell Type</b>	B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
<b>Biology Area</b>	Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
<b>Molecular Family</b>	CD Molecules
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Barclay A, <i>et al.</i> 1997. <i>The Leukocyte Antigen FactsBook</i> Academic Press.</li> <li>2. Trowbridge IS, <i>et al.</i> 1993. <i>Annu. Rev. Immunol.</i> 12:85.</li> <li>3. Kishihara K, <i>et al.</i> 1993. <i>Cell</i> 74:143.</li> <li>4. Pulido R, <i>et al.</i> 1988. <i>J. Immunol.</i> 140:3851.</li> </ol>
<b>Gene ID</b>	<a href="#">19264</a>

## Related Protocols


[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats


APC anti-mouse CD45, Biotin anti-mouse CD45, FITC anti-mouse CD45, PE anti-mouse CD45, PE/Cyanine5 anti-mouse CD45, Purified anti-mouse CD45, PE/Cyanine7 anti-mouse CD45, APC/Cyanine7 anti-mouse CD45, Alexa Fluor® 488 anti-mouse CD45, Alexa Fluor® 647 anti-mouse CD45, Pacific Blue™ anti-mouse CD45, Alexa Fluor® 700 anti-mouse CD45, PerCP/Cyanine5.5 anti-

mouse CD45, PerCP anti-mouse CD45, Alexa Fluor® 594 anti-mouse CD45, Brilliant Violet 421™ anti-mouse CD45, Brilliant Violet 570™ anti-mouse CD45, Brilliant Violet 510™ anti-mouse CD45, Brilliant Violet 605™ anti-mouse CD45, Purified anti-mouse CD45 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse CD45, Brilliant Violet 711™ anti-mouse CD45, Brilliant Violet 785™ anti-mouse CD45, Brilliant Violet 650™ anti-mouse CD45, APC/Fire™ 750 anti-mouse CD45, Brilliant Violet 750™ anti-mouse CD45, TotalSeq™-A0096 anti-mouse CD45, TotalSeq™-B0096 anti-mouse CD45, Ultra-LEAF™ Purified anti-mouse CD45, Spark Blue™ 550 anti-mouse CD45, Spark NIR™ 685 anti-mouse CD45, TotalSeq™-C0096 anti-mouse CD45, Spark YG™ 570 anti-mouse CD45, PE/Fire™ 640 anti-mouse CD45, APC/Fire™ 810 anti-mouse CD45, PE/Fire™ 700 anti-mouse CD45, Spark Violet™ 538 anti-mouse CD45, Spark YG™ 593 anti-mouse CD45, Spark Blue™ 574 anti-mouse CD45 Antibody

## Product Data



BALB/c splenocytes stained with 30-F11 purified, followed by anti-rat IgG FITC



Fresh, frozen mouse spleen was stained with purified CD45 clone 30-F11 conjugated and detected with a FITC CODEX™ oligonucleotide duplex (red). Samples were counterstained with Collagen IV Cy5 (green). Data generated at Akoya Biosciences, Inc. using the CODEX™ technology.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587